Jonathan Scott Harrison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jonathan Scott Harrison has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
Xuening Wang
Department of Pathology & Laboratory Medicine, New Jersey Medical School, Rutgers, Newark, NJ, 07103, USA
11 shared publications- George P. Studzinski
Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA
8 shared publications - George P. Studzinski
Department of Pathology and Laboratory Medicine, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA
8 shared publications - Michael Danilenko
Department of Clinical Biochemistry & Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel
7 shared publications Jing Qian
4 shared publicationsPranela Rameshwar
4 shared publications
Latest Publications
- Open Access
- 16 February 2022
- Published by IntechOpen
Non-Alzheimers Amyloidoses of the Neurological System: Cerebral Amyloid Angiopathy and Familial Amyloid Polyneuropathy
Amyloid deposition plays a significant, albeit overlooked, role in neurologic disorders. Deposition of amyloid proteins in both the central and peripheral nervous systems lead to debilitating, and often deadly, organ dysfunction, including cerebral amyloid angiopathy, familial amyloid neuropathy, and Alzheimer’s disease (AD). Alzheimer’s disease is discussed in some detail in a separate chapter within this book, and therefore will not be discussed in detail in this chapter. In this chapter, we present the pathological mechanisms, disease manifestations, diagnostic approach, and treatment modalities for diseases of the nervous system caused by amyloid deposition. While significant strides have been made over the years in identifying key underlying pathologic mechanisms, the medical community’s understanding of these rare conditions remain limited. The primary goal of this chapter is to provide additional resources and information for clinicians to help identify these disorders early in their course before they cause irreparable damage to their patients.
- 16 February 2022
- Published by IntechOpen
Open AccessNon-Alzheimers Amyloidoses of the Neurological System: Cerebral Amyloid Angiopathy and Familial Amyloid Polyneuropathy
Amyloid deposition plays a significant, albeit overlooked, role in neurologic disorders. Deposition of amyloid proteins in both the central and peripheral nervous systems lead to debilitating, and often deadly, organ dysfunction, including cerebral amyloid angiopathy, familial amyloid neuropathy, and Alzheimer’s disease (AD). Alzheimer’s disease is discussed in some detail in a separate chapter within this book, and therefore will not be discussed in detail in this chapter. In this chapter, we present the pathological mechanisms, disease manifestations, diagnostic approach, and treatment modalities for diseases of the nervous system caused by amyloid deposition. While significant strides have been made over the years in identifying key underlying pathologic mechanisms, the medical community’s understanding of these rare conditions remain limited. The primary goal of this chapter is to provide additional resources and information for clinicians to help identify these disorders early in their course before they cause irreparable damage to their patients.
- Open Access
- 16 February 2022
- Published by IntechOpen
An Historical Overview of the Amyloidoses
The amyloidoses are a heterogenous group of clinical disorders that share the common finding of the abnormal deposition of insoluble proteins into various organs, with the result that these proteinaceous deposits disrupt cellular function and impair the integrity of the organs involved. Most typically, the abnormal protein deposition is the consequence of abnormal three dimensional folding of the culprit protein. The abnormal folding of the protein, in turn, may be due to a germ line mutation, may be due to an acquired mutation, or may be due to a polymorphism or characteristic of a normal protein that leads to abnormal folding, precipitation, and deposition of the protein, particularly when that protein is expressed at unusually high levels for a prolonged period of time. The clinical manifestations of an amyloid disorder are the consequences of the array of organs involved, the extent of amyloid deposition, and co-morbid conditions present in the individual patient. The array of organs involved, and the extent of organ involvement, in turn, depend in large part on the specific protein that is responsible for the amyloid deposition, and the process driving that protein’s production. In this chapter, a chronological overview is intended to summarize the critical insights into the patho-biology of amyloid accumulation of various types. These insights have allowed an improved understanding over time of the of the major subgroups and disease entities of the amyloidoses, leading to some degree of improvement in diagnosis and treatment outcomes. Unfortunately, as of this writing, treatment outcomes still remain poor for a large fraction of patients, and there is need for improvement in all aspects of the evaluation and management of these diseases.
- 16 February 2022
- Published by IntechOpen
Open AccessAn Historical Overview of the Amyloidoses
The amyloidoses are a heterogenous group of clinical disorders that share the common finding of the abnormal deposition of insoluble proteins into various organs, with the result that these proteinaceous deposits disrupt cellular function and impair the integrity of the organs involved. Most typically, the abnormal protein deposition is the consequence of abnormal three dimensional folding of the culprit protein. The abnormal folding of the protein, in turn, may be due to a germ line mutation, may be due to an acquired mutation, or may be due to a polymorphism or characteristic of a normal protein that leads to abnormal folding, precipitation, and deposition of the protein, particularly when that protein is expressed at unusually high levels for a prolonged period of time. The clinical manifestations of an amyloid disorder are the consequences of the array of organs involved, the extent of amyloid deposition, and co-morbid conditions present in the individual patient. The array of organs involved, and the extent of organ involvement, in turn, depend in large part on the specific protein that is responsible for the amyloid deposition, and the process driving that protein’s production. In this chapter, a chronological overview is intended to summarize the critical insights into the patho-biology of amyloid accumulation of various types. These insights have allowed an improved understanding over time of the of the major subgroups and disease entities of the amyloidoses, leading to some degree of improvement in diagnosis and treatment outcomes. Unfortunately, as of this writing, treatment outcomes still remain poor for a large fraction of patients, and there is need for improvement in all aspects of the evaluation and management of these diseases.
- Open Access
- 5 February 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (3) , 491-497
Primary central nervous system marginal zone B‐cell lymphoma arising from the dural meninges: A case report and review of literature
Primary central nervous system (CNS) marginal zone B‐cell lymphoma (MZBCL) arising from the dural meninges is a rare but indolent disease. This malignancy can present in various ways, hence making it difficult to diagnose. Biopsy results dictate an appropriate treatment plan, which commonly consists of a combination of surgical resection, whole brain radiotherapy and systemic therapy.
- 5 February 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (3) , 491-497
Open AccessPrimary central nervous system marginal zone B‐cell lymphoma arising from the dural meninges: A case report and review of literature
Primary central nervous system (CNS) marginal zone B‐cell lymphoma (MZBCL) arising from the dural meninges is a rare but indolent disease. This malignancy can present in various ways, hence making it difficult to diagnose. Biopsy results dictate an appropriate treatment plan, which commonly consists of a combination of surgical resection, whole brain radiotherapy and systemic therapy.
- Open Access
- 7 August 2019
- Published by IntechOpen
The Clinical Spectrum of Amyloidosis
Amyloidosis is a group of disorders that share a common pathobiology: in each case, a protein that exhibits misfolding is deposited in one or multiple organs leading to disruption in organ function. These amyloid proteins are recognized as amorphous pink material in Hematoxylin and Eosin staining, with confirmation by staining with Congo red and yellow or green birefringence under polarized light microscope. To date at least 36 different types of amyloid proteins have been identified. Worldwide, AA amyloidosis is the most common type, and this occurs secondary to chronic inflammatory disease states—such as chronic infections and rheumatological disorders. In western countries, the incidence of AA amyloidosis is decreasing, and AL is the most common type of amyloidosis, characterized by amyloid due to light chain deposition. ATTR amyloidosis, which can be either hereditary or acquired, is a unique variant of systemic amyloidosis that results from mutations in the transthyretin (TTR) gene. Our review will focus on clinical features of the most common systemic amyloidosis, with a detailed review on evaluation and management of AA, AL and ATTR amyloidosis.
- 7 August 2019
- Published by IntechOpen
Open AccessThe Clinical Spectrum of Amyloidosis
Amyloidosis is a group of disorders that share a common pathobiology: in each case, a protein that exhibits misfolding is deposited in one or multiple organs leading to disruption in organ function. These amyloid proteins are recognized as amorphous pink material in Hematoxylin and Eosin staining, with confirmation by staining with Congo red and yellow or green birefringence under polarized light microscope. To date at least 36 different types of amyloid proteins have been identified. Worldwide, AA amyloidosis is the most common type, and this occurs secondary to chronic inflammatory disease states—such as chronic infections and rheumatological disorders. In western countries, the incidence of AA amyloidosis is decreasing, and AL is the most common type of amyloidosis, characterized by amyloid due to light chain deposition. ATTR amyloidosis, which can be either hereditary or acquired, is a unique variant of systemic amyloidosis that results from mutations in the transthyretin (TTR) gene. Our review will focus on clinical features of the most common systemic amyloidosis, with a detailed review on evaluation and management of AA, AL and ATTR amyloidosis.
- Open Access
- 1 December 2018
- Published by Rivera Publications Inc. in Clinical & Medical Cases
- Vol. 1 (1)
Rituximab in Relapsing acquired Thrombotic Thrombocytopenic Purpura: Experience and Evidence
Thrombotic Thrombocytopenic Purpura (TTP), first described in the early twentieth century, was fatal in the majority of cases until the advent of plasma therapy. Mortality has declined dramatically since the 1980s, and in the 1990s the pathophysiology was elucidated through the discovery and understanding of the central role of a deficiency of the metalloprotease ADAMTS13. The vast majority of cases occur due to an autoimmune process, with a minority of cases due to an underlying mutation. Since the turn of this century, Rituximab, a monoclonal antibody targeting CD20 expressed on B-lymphocytes, has become widely used to treat patients with a wide spectrum of autoimmune diseases, including TTP. However, Rituximab remains “off-label” in the setting of TTP. We recently encountered a patient with chronic relapsing TTP, whose clinical relapses have responded to Rituximab-based therapy without need to resort to plasmapheresis. The clinical course of this patient is described, and the literature focusing on the use of Rituximab in prophylaxis to prevent recurrent TTP is reviewed.
- 1 December 2018
- Published by Rivera Publications Inc. in Clinical & Medical Cases
- Vol. 1 (1)
Open AccessRituximab in Relapsing acquired Thrombotic Thrombocytopenic Purpura: Experience and Evidence
Thrombotic Thrombocytopenic Purpura (TTP), first described in the early twentieth century, was fatal in the majority of cases until the advent of plasma therapy. Mortality has declined dramatically since the 1980s, and in the 1990s the pathophysiology was elucidated through the discovery and understanding of the central role of a deficiency of the metalloprotease ADAMTS13. The vast majority of cases occur due to an autoimmune process, with a minority of cases due to an underlying mutation. Since the turn of this century, Rituximab, a monoclonal antibody targeting CD20 expressed on B-lymphocytes, has become widely used to treat patients with a wide spectrum of autoimmune diseases, including TTP. However, Rituximab remains “off-label” in the setting of TTP. We recently encountered a patient with chronic relapsing TTP, whose clinical relapses have responded to Rituximab-based therapy without need to resort to plasmapheresis. The clinical course of this patient is described, and the literature focusing on the use of Rituximab in prophylaxis to prevent recurrent TTP is reviewed.
- Open Access
- 11 March 2018
- Published by Wiley in Clinical Case Reports
- Vol. 6 (5) , 847-850
Large granular lymphocytic leukemia complicating autoimmune polyglandular syndrome type 1 in siblings
Key Clinical Message: Autoimmune polyglandular syndrome type 1 (APS1) is a rare autosomal recessive disorder, and large granular lymphocytic leukemia (LGLL) may, even more rarely, complicate APS1. LGLL may be subtle in presentation, but it is imperative to recognize LGLL in APS1 promptly, as outcome may otherwise be fatal, as described herein.
- 11 March 2018
- Published by Wiley in Clinical Case Reports
- Vol. 6 (5) , 847-850
Open AccessLarge granular lymphocytic leukemia complicating autoimmune polyglandular syndrome type 1 in siblings
Key Clinical Message: Autoimmune polyglandular syndrome type 1 (APS1) is a rare autosomal recessive disorder, and large granular lymphocytic leukemia (LGLL) may, even more rarely, complicate APS1. LGLL may be subtle in presentation, but it is imperative to recognize LGLL in APS1 promptly, as outcome may otherwise be fatal, as described herein.
- 1 March 2018
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 177, 149-154
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML
- 1 March 2018
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 177, 149-154
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML
- 1 October 2017
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 173, 139-147
BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents
- 1 October 2017
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 173, 139-147
BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents
- 1 June 2017
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 28 (4) , 342-347
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis
Acquired coagulopathies are common; uncommonly, adsorption of coagulation factors from the circulation into the tissues by pathologic amyloid exceeds the body's ability to produce factor and results in acquired factor deficiency. When amyloidosis does cause a coagulopathy, it is most often acquired factor X deficiency, but there are rare reports of amyloidosis being associated with other acquired factor deficiencies. We investigated a case of a severe bleeding diathesis, the cause of which was combined acquired factor V deficiency and concomitant acquired von Willebrand syndrome. Studies revealed prolonged prothrombin time and activated partial thromboplastin time. Mixing patient plasma with normal plasma corrected both the prothrombin time and activated partial thromboplastin time. Assays showed decreased factor V activity of 27%; Ristocetin cofactor activity was decreased at 49%, but von Willebrand antigen was elevated at 213%. Multimer analysis was consistent with type 2 von Willebrand syndrome. Lymph node biopsy documented amyloid light chain type (AL) amyloidosis; extraction of protein from the lymph node documented AL lambda light chain amyloid. Marrow biopsy documented IgG lambda myeloma. Immunohistochemical staining of the lymph node, using investigational polyvalent antibodies, demonstrated that both von Willebrand factor and factor V were identifiable in areas of amyloid deposition, providing evidence that these coagulation factors were adsorbed to the amyloid protein, resulting in accelerated clearance from the circulation, previously reported to be the mechanism of cases of acquired factor X deficiency in the setting of amyloidosis. Although there are case reports of acquired von Willebrand syndrome because of amyloidosis and case reports of acquired factor V deficiency because of amyloidosis, this appears to be the first reported case of concomitant acquired von Willebrand syndrome and acquired factor V deficiency because of amyloidosis, and the first report of localization of both von Willebrand protein and factor V protein to AL amyloid as a cause of a severe bleeding diathesis
- 1 June 2017
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 28 (4) , 342-347
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis
Acquired coagulopathies are common; uncommonly, adsorption of coagulation factors from the circulation into the tissues by pathologic amyloid exceeds the body's ability to produce factor and results in acquired factor deficiency. When amyloidosis does cause a coagulopathy, it is most often acquired factor X deficiency, but there are rare reports of amyloidosis being associated with other acquired factor deficiencies. We investigated a case of a severe bleeding diathesis, the cause of which was combined acquired factor V deficiency and concomitant acquired von Willebrand syndrome. Studies revealed prolonged prothrombin time and activated partial thromboplastin time. Mixing patient plasma with normal plasma corrected both the prothrombin time and activated partial thromboplastin time. Assays showed decreased factor V activity of 27%; Ristocetin cofactor activity was decreased at 49%, but von Willebrand antigen was elevated at 213%. Multimer analysis was consistent with type 2 von Willebrand syndrome. Lymph node biopsy documented amyloid light chain type (AL) amyloidosis; extraction of protein from the lymph node documented AL lambda light chain amyloid. Marrow biopsy documented IgG lambda myeloma. Immunohistochemical staining of the lymph node, using investigational polyvalent antibodies, demonstrated that both von Willebrand factor and factor V were identifiable in areas of amyloid deposition, providing evidence that these coagulation factors were adsorbed to the amyloid protein, resulting in accelerated clearance from the circulation, previously reported to be the mechanism of cases of acquired factor X deficiency in the setting of amyloidosis. Although there are case reports of acquired von Willebrand syndrome because of amyloidosis and case reports of acquired factor V deficiency because of amyloidosis, this appears to be the first reported case of concomitant acquired von Willebrand syndrome and acquired factor V deficiency because of amyloidosis, and the first report of localization of both von Willebrand protein and factor V protein to AL amyloid as a cause of a severe bleeding diathesis